Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association
Open Access
- 25 February 2021
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (5), 1231-1233
- https://doi.org/10.3324/haematol.2020.275933
Abstract
No abstract availableThis publication has 90 references indexed in Scilit:
- Regulation of Janus kinases by SOCS proteinsBiochemical Society Transactions, 2013
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013
- Age-related differences in disease characteristics and clinical outcomes in polycythemia veraLeukemia & Lymphoma, 2013
- JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneBlood, 2012
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With MyelofibrosisMayo Clinic Proceedings, 2011
- The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signalingNature Structural & Molecular Biology, 2011
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdensExperimental Hematology, 2008
- Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid CancersClinical Cancer Research, 2008
- Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significanceBritish Journal of Haematology, 2007